Acceleron Pharma (XLRN) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as higher oil prices temper risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
Acceleron Reports Fourth Quarter and Year Ended 2016 Operational and Financial Results
March 1, 2017 7:02 AM EST- Luspatercept Phase 3 trials to complete enrollment in both the MDS (MEDALIST) and beta-thalassemia (BELIEVE) trials in 2H 2017 -
- Presented data from five abstracts on luspatercept and sotatercept at the American Society of Hematology Annual Meeting in December -
- Treated first patient in ACE-083 Phase 2 study for facioscapulohumeral muscular dystrophy -
- Outlined plans to initiate several new clinical trials in 2017 -
- Maintained strong balance sheet with $234.4 million in cash and investments to fund projected operating requirements into... More
